for people ages 18 years and up (full criteria)
at UC Davis
study started
estimated completion
Principal Investigator
by Julie L. Sutcliffe, PhD (ucdavis)



This study investigates fluorine-18-AlphaVBeta6-BP ([18F]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. Investigators hypothesize that [18F]-αvβ6-BP PET/Computed Tomography (CT) is a sensitive tool for disease assessment in patients with metastatic NSCLC, including those with brain metastases.

Official Title

Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography for Staging, Response Assessment, and Patient Selection in Metastatic Non-Small Cell Lung Cancer


PRIMARY OBJECTIVE: The primary objective of this study is to evaluate the sensitivity and specificity of [18F]-αvβ6-BP PET/CT for detecting metastases in patients with NSCLC. OUTLINE: Patients will undergo [18F]-αvβ6-BP PET/CT at baseline in addition to standard-of-care [18F]-2-fluoro-2-deoxy-D-glucose (FDG) PET/CT body and magnetic resonance imaging (MRI) of the brain. Patients will then undergo standard-of-care cancer directed therapy. Patients will be re-staged 8-12 weeks later at the next standard-of-care imaging time point with [18F]-αvβ6-BP PET/CT, [18F]-FDG PET/CT, and MRI.


Lung Cancer, Lung Cancer Metastatic, Brain Metastases, Non Small Cell Lung Cancer, Positron Emission Tomography, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, [18F]-αvβ6-BP


You can join if…

Open to people ages 18 years and up

  1. Men and women age >18 yrs
  2. Biopsy proven NSCLC with brain metastases (treated or untreated)
  3. Life-expectancy of ≥3 months in the opinion of the treating physician
  4. Available archival tumor tissue (excisional, core, or fine needle aspiration (FNA) is acceptable). Tissue from a metastatic site is preferred when available.
  5. Able to tolerate all study procedures, including remain motionless for up to 30-60 minutes per scan
  6. Ability to understand and willingness to sign a written informed consent document.
  7. Planned to undergo additional cancer-directed therapy followed by standard-of-care re-staging imaging
  8. [18F]-FDG PET/CT within 21 days of enrollment
  9. MRI brain within 21 days of enrollment
  10. . Eastern Cooperative Oncology Group Performance Status ≤ 2
  11. . Glomerular filtration rate (GFR) ≥ 60

You CAN'T join if...

  1. Pregnant or lactating women
  2. Prisoners
  3. Concurrent malignancy of a different histology that could confound imaging interpretation
  4. Patients who cannot undergo PET/CT scanning because of weight limits(>350lbs)


  • The University of California Davis Comprehensive Cancer Center accepting new patients
    Sacramento California 95817 United States

Lead Scientist at UC Cancer

  • Julie L. Sutcliffe, PhD (ucdavis)
    Professor, Hematology and Oncology, School of Medicine. Authored (or co-authored) 61 research publications


accepting new patients
Start Date
Completion Date
University of California, Davis
Phase 1 research study
Study Type
Expecting 20 study participants
Last Updated